Nishida T, et al. - This research was designed to assess the efficacy, safety, and tolerability of perampanel, a selective, non-competitive, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, as an adjunctive treatment for patients with refractory partial-onset seizures (POS) from Asia-Pacific. In patients with refractory POS, adjunctive perampanel (8 and 12 mg/d) significantly improved seizure control. At daily doses of perampanel 4-12 mg, safety and tolerability were acceptable.